[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson39s-disease-pd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson39s-disease-pd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,77,102,127,155,186,217,243,263,293,322,353,376,400,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100585181","attention-and-eye-movement-in-parkinsons-disease-100585181",false,"NCT06899022","Attention and Eye Movement in Parkinson's Disease","Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease","Inclusion Criteria\n\n* All Participants (Aim 1):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n* DBS Participants (Aim 1):\n\n  * Diagnosis of idiopathic Parkinson's disease (PD), essential tremor (ET) or dystonia (DT).\n  * Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi)\n* Comparison Participants (Aim 1):\n\n  o Selection by age matching to participants in PD group\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n  * Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER)\n  * Willing and able to engage in tasks during an awake surgical procedure\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):\n\n  * Ability and willingness to provide signed informed consent for this study\n  * Ability to express perceptual judgments through a button press or mouse- controlled computerized slider\n  * Age 19 - 90 years\n  * Willing to undergo acute manipulations of DBS\n  * Able to tolerate acute changes of DBS\n\nExclusion Criteria\n\n* All Participants (Aim 1):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n* DBS Participants (Aim 1):\n\n  o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider\n* Healthy Comparison Participants (Aim 1):\n\n  o History of neurodegenerative disorder\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n  * Not undergoing awake DBS implantation\n  * Uncorrected visual acuity insufficient to perceptually judge face stimuli\n* Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):\n\n  * Corrected visual acuity insufficient to perceptually judge face stimuli\n  * Inability to understand task instructions or complete task requirements\n  * Failure of DBS to achieve a therapeutic effect on motor symptoms",true,"ALL","19 Years","90 Years",{"count":21,"type":22},138,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and non-PD movement disorders, including essential tremor (ET) and dystonia (DT). The main questions it aims to answer are:\n\n* Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted?\n* Does therapeutic DBS improve or worsen attentional and perceptual deficits for social cues in PD, ET and DT?\n* Can DBS be optimized to restore normal attentional control in PD while remaining an effective therapy for other aspects of the disorder.\n* What do parts of the brain targeted by DBS contribute to the control of attention?\n\nUsing an eye tracking camera, investigators will study how participants with PD, ET and DT look at and perceive facial expressions of emotion before and after starting DBS therapy, in comparison to a group of healthy participants without ET, PD, DT or DBS. Participants with PD, ET and DT will see and rate morphed facial expressions on a computer screen in three conditions:\n\n* Before starting DBS therapy (over approximately 1 hour).\n* In the operating room, during the standard procedure to implant DBS electrodes, while the participant is awake (for no more than 15 minutes).\n* After starting DBS therapy, with brief experimental changes of DBS stimulation level and frequency (over approximately 1 hour).",[28,29,30],"Essential Tremor","Parkinson's Disease (PD)","Dystonias",[32,33,34,35],"Deep Brain Stimulation","Attention","Perception","Eye movement","RECRUITING","2026-04-30",{"date":39,"type":40},"2026-05-05","ACTUAL",{"date":42,"type":40},"2025-09-22",{"date":44,"type":22},"2028-08",{"name":46,"class":47},"University of Nebraska","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100628601","low-fidelity-driving-simulator-training-in-parkinsons-disease-100628601","NCT07463755","Low-Fidelity Driving Simulator Training in Parkinson's Disease.","Low-Fidelity Driving Simulator Training and Driving Outcomes in Parkinson's Disease: A Pilot Randomized Control Study","Inclusion Criteria:\n\n* Individuals with Parkinson's disease diagnosed by a movement disorder specialist.\n* Diagnosis of PD was based on the UK Brain Bank Diagnostic Criteria.\n* Hoehn and Yahr stage 1 to 3 in the medication ON state with no troublesome dyskinesia.\n* Minimum binocular acuity of 20\u002F40 or better at least in one eye according to the Kansas DMV statutes.\n* Montreal Cognitive Assessment (MoCA) ≥ 20.\n* Ambulates independently with or without walking aids.\n* Possess a valid driver's license.\n\nExclusion Criteria:\n\n* Any concomitant neurological comorbidity, such as stroke, traumatic brain injury, or multiple sclerosis, that would hinder driving.\n* Atypical forms of Parkinsonism\n* History of substance abuse in the last 10 years.\n* History of uncontrolled psychiatric problems\n* Undergone deep brain stimulation or focused ultrasound treatment\n* Uncontrolled diabetes mellitus","30 Years",{"count":58,"type":22},36,[25],"The goal of this clinical trial is to learn if low-fidelity driving simulator training works to improve cognitive performance, driving behavior, and driving aptitude in individuals with Parkinson's disease. The main questions it aims to answer are:\n\n* Does low-fidelity driving simulator training improve cognitive performance?\n* Does low-fidelity driving simulator training improve driving performance?\n* Does low-fidelity driving simulator training improve driving aptitude?\n\nResearchers will compare driving simulator training to no-training (waitlist control group) to see if the low-fidelity driving simulator is effective in individuals with Parkinson's disease.\n\nParticipants will:\n\n* Undergo 10 sessions of driving simulator training or be placed in the no-training group.\n* Training group participants will visit the driving simulator lab 2-3 times a week for 4 weeks for training.\n* Paper-based tests and driving simulator tests will be done before and after 10 sessions of training (or a waiting period).",[29],[63,64,65,66],"Low-fidelity driving simulator","Parkinson's disease","Cognitive performance","Driving performance","NOT_YET_RECRUITING","2026-03-09",{"date":70,"type":40},"2026-03-11",{"date":72,"type":22},"2026-04-15",{"date":74,"type":22},"2027-04-30",{"name":76,"class":47},"University of Kansas Medical Center",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":48},"100622344","developing-immersive-gamification-technology-systems-for-the-rehabilitation-management-of-adults-with-parkinsons-disease-phase-1-trial-100622344","NCT07382401","Developing Immersive Gamification Technology Systems For The Rehabilitation Management Of Adults With Parkinson's Disease (Phase 1 Trial)","Inclusion Criteria:\n\n* Aged 50 to 70 years old\n* Able to understand Filipino and English\n* Montreal Cognitive Assessment - Philippines (MOCA-P) score \\>27\n* Timed Up and Go \\\u003C10 seconds\n\nExclusion Criteria:\n\n* Previously diagnosed with any neurologic condition\n* With any form of aphasia\n* Previously diagnosed with a psychiatric disorder\n* Previously diagnosed with seizures or epilepsy\n* Significant visual or hearing impairment (including individuals who have difficulties seeing or hearing even with the use of assistive devices like eyeglasses or hearing aids) or use of mobility aids\n* Has a history of motion sickness\n* Has quadriplegia or paralysis of dominant hand\n* Has a life expectancy of less than a year\n* Has previously used an ImGTS (e.g., a head-mounted display (HMD) or a cave automatic virtual environment (CAVE))","50 Years","70 Years",{"count":86,"type":22},30,[25],"This clinical trial aims to develop and test a prototype immersive gamification technology system (ImGTS) among healthy volunteers and to determine its acceptability, safety, and usability in a healthy population. The main question it aims to answer is:\n\nDoes ImGTS provide an acceptable, safe, and usable therapeutic modality for patients with Parkinson's Disease? Researchers will compare a head-mounted display (HMD) system and a semi cave automatic virtual environment (semi-CAVE) system to see if they are acceptable, safe, and usable as therapy for PD.\n\nParticipants will be will undergoing their assigned ImGTS intervention for four sessions (twice a week for two weeks) supervised by a trained therapist. Afterwards, they will be interviewed based on specific questionnaires used to check for acceptability, safety, and usability.",[90,29],"Parkinson Disease",[90,92,93],"Rehabilitation","Immersive Technology","2026-01-28",{"date":96,"type":40},"2026-02-02",{"date":98,"type":22},"2026-02-01",{"date":37,"type":22},{"name":101,"class":47},"Augmented eXperience E-health Laboratory",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100591608","accelerated-tms-for-freezing-of-gait-in-parkinsons-disease-100591608","NCT06982638","Accelerated TMS for Freezing of Gait in Parkinson's Disease","TMS","Inclusion Criteria:\n\n1. 50-80 years of age\n2. diagnosis of PD based on UK Brain Bank diagnostic criteria 55\n3. presence of FOG defined as a score of 1 on part 1 of the nFOGQ in which a video showing different types of freezing is played for the patient, a score of 1 represents a positive response of having experienced such an episode over the last month\n4. no dopaminergic medication changes in the month prior\n5. observed FOG rated as \\>1 in item 3.11 of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).\n\nExclusion Criteria:\n\n1. a history of other significant gait impairment unrelated to PD (e.g. orthopedic deformities)\n2. inability to complete gait assessments (timed up and go task) without assistance or assist devices\n3. barriers to making contact between the TMS coil and the skin (e.g. braids that cannot be removed)\n4. failing to meet all criteria on a standardized MRI\u002FTMS safety screening: This includes, but is not limited to, the presence of claustrophobia, implanted electronic devices (e.g., pacemakers), metallic objects or fragments (e.g., bullets), and non-removable hair clips or piercings.\n5. individuals with a diagnosis of psychosis or any other cognitive impairments that would make them unable to understand and follow study instructions or to consent for themselves.\n6. pregnancy\n7. individuals with a history of seizure","80 Years",{"count":111,"type":22},12,[25],"The goal of this clinical trial is to learn whether a personalized brain stimulation method called repetitive transcranial magnetic stimulation (rTMS), combined with walking exercises, is a practical and tolerable approach to help people with Parkinson's disease who experience freezing of gait (FOG). FOG is a disabling symptom where people temporarily feel stuck and unable to start walking, even though they want to move.\n\nThe main questions this study aims to answer are:\n\nCan people with Parkinson's disease and FOG tolerate this combined rTMS and walking training procedure?\n\nCan researchers successfully enroll and retain participants for this multi-visit intervention?\n\nDoes the combination of rTMS and gait training show early signs of improving gait and reducing freezing episodes?\n\nThis study does not include a comparison or placebo group. All participants will receive the same intervention.\n\nParticipants will:\n\nAttend up to 15 study visits over about 16 weeks, with the option to combine visits to reduce burden.\n\nComplete brain imaging (MRI) before and after the intervention to guide and evaluate treatment.\n\nReceive a form of brain stimulation (rTMS) using a safe, non-invasive coil placed over a specific part of the brain called the supplementary motor area (SMA). The target is personalized using each person's MRI data.\n\nParticipate in walking exercises that include cognitive tasks (dual-task gait training) after each set of brain stimulation sessions.\n\nUndergo assessments of walking ability, Parkinson's disease symptoms, and brain response to stimulation.\n\nBe videotaped during walking tasks to assess gait changes, while wearing small motion sensors on the body.\n\nComplete questionnaires about symptoms, safety, and tolerability.\n\nThis study is being conducted at the Medical University of South Carolina (MUSC) and includes up to 15 adults between the ages of 50 and 80 who have been diagnosed with Parkinson's disease and experience FOG.\n\nAlthough rTMS is already FDA-cleared for depression and other conditions, it has not been approved for freezing of gait, and its use in this study is considered investigational. The stimulation device used has been determined to be non-significant risk (NSR) by the FDA.\n\nThe study does not offer direct medical benefit to participants, but results from this trial may help researchers develop future treatments and better understand how brain stimulation affects walking difficulties in Parkinson's disease.\n\nParticipation is voluntary, and individuals can withdraw from the study at any time without affecting their medical care",[29],[107,29,116,117],"Gait training","Freezing of gait","2026-01-05",{"date":120,"type":40},"2026-01-07",{"date":122,"type":40},"2024-11-21",{"date":124,"type":22},"2026-12-31",{"name":126,"class":47},"Medical University of South Carolina",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100615807","prevention-in-pd-study-100615807","NCT07297407","Prevention-in-PD-Study","PREVENTION-IN-PD - Development of a Multidomain Lifestyle Intervention Study for Prodromal and Clinical Parkinson's Disease","Inclusion Criteria:\n\n* All participants: ability to perform informed consent; age 30-85\n* RBD group: polysomnographic proven diagnosis of isolated REM sleep behavior disorder (iRBD)\n* PD group: early to moderate disease (Hoehn \\& Yahr stage 1-2.5), diagnosis according to the Movement Disorder Society diagnostic criteria for clinical Parkinson's Disease\n* Agreement to participate in group sessions and online meetings\n\nExclusion Criteria:\n\n* dementia (Mini Mental Score, MMSE \\\u003C 19 points) (MMSE is specifically chosen here to avoid too frequent repetitions of the MoCA, which is used as an outcome parameter for the interventional trial)\n* physical inability to perform exercise training or other trainings as judged by a physician\n* manifest (severe) depression (Beck Depression Inventory, BDI-II \\> 29 points)\n* participation in other interventional trials\n* other significant diseases of the central nervous system\n* Planned change in medication within the following 6 months","85 Years",{"count":136,"type":22},99,[25],"The goal of this clinical trial (feasibility study) is to learn if a multimodal lifestyle program can improve adherence to recommended lifestyle changes in people with REM Sleep Behavior Disroder (RBD) or Parkinson's disease (PD).\n\nThe main question it aims to answer is if individuals with RBD oder PD can follow a combined lifestyle program over six months Participants will take part in a six-month intervention program that includes: Physical training, Mediterranean diet counseling, Sleep counseling and cognitive training.\n\nThe program will be supported by psychoeducation, skills training, and personalization to make it practical and motivating.",[29],[141,142,143,144,145],"lifestyle","exercise","nutrition","cognitive training","sleep","2025-12-16",{"date":148,"type":40},"2025-12-22",{"date":150,"type":22},"2026-04-01",{"date":152,"type":22},"2027-09",{"name":154,"class":47},"University Hospital Schleswig-Holstein",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":163,"maxAge":109,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100609333","pet-mri-of-reward-system-in-parkinsons-disease-with-rbd-100609333","NCT07213219","PET-MRI of Reward System in Parkinson's Disease With RBD","Exploration of the Reward System in Parkinson's Patients With Paradoxical Sleep Behavior Disorders: a Multimodal Imaging Study","RBD Impulse","Inclusion Criteria:\n\n* Patients aged 45 to 80 years\n* Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria\n* Disease duration between 3 and 7 years\n* Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration\n* Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol\n* Patients affiliated with or beneficiaries of a social security system\n* Volunteer patients capable of providing informed consent to participate in the research\n\nExclusion Criteria:\n\n* Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD)\n* Patients with severe depression (Beck Depression Inventory \\\\\\[20\\] (BDI) score \\> 30), apathy (Starkstein scale \\\\\\[21\\] score ≥ 14), cognitive impairment (Montreal Cognitive Assessment \\\\\\[MoCA\\] \\\\\\[22\\] score \\\u003C 25), or impulse control disorders (QUIP - Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease \\\\\\[23\\], score ≥ 1)\n* Patients with severe motor symptoms: patients with an MDS-UPDRS III score \\> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection\n* Pregnant or breastfeeding women\n* Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances)\n* Refusal to participate","45 Years",{"count":165,"type":22},44,[25],"Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The mechanisms leading to ICDs in PD remain debated, but it has been shown that the dopaminergic mesocorticolimbic pathways play a key role in reward, learning, and reinforcement processes, as well as in the regulation of impulsivity. PET studies using \\[11C\\]raclopride, a tracer that allows evaluation of the postsynaptic availability of dopamine D2\u002FD3 receptors, have demonstrated abnormal sensitization of the mesocorticolimbic dopaminergic system (the reward system), particularly in the ventral striatum, in Parkinson's patients with ICDs when presented with appetitive stimuli or during gambling tasks. However, this has never been studied in patients with and without RBD. Parkinson's patients with RBD may present greater impairment of mesocorticolimbic pathways than those without RBD, particularly abnormal sensitization and postsynaptic modifications of the dopaminergic system, which could predispose patients to the emergence of ICDs when exposed to dopaminergic agonists. Confirming a particular pattern of denervation in Parkinson's patients with RBD that may favor the emergence of ICDs constitutes a personalized medicine approach with a readily identifiable risk marker in routine clinical practice and offers the possibility of adapting the management of these patients.\n\nThe main objective of this study is to investigate the availability of D2 dopaminergic receptors in subcortical structures (particularly the mesocorticolimbic system) in patients with idiopathic Parkinson's disease, depending on the presence or absence of RBD",[29],[170,171,172,173,174,175],"Impulse Control Disorders","Rapid Eye Movement Sleep Behavior Disorder","Parkinson's Disease","Positron Emission Tomography","[¹¹C]raclopride","Magnetic Resonance Imaging","2025-12-02",{"date":178,"type":40},"2025-12-03",{"date":180,"type":22},"2026-01-01",{"date":182,"type":22},"2029-01-01",{"name":184,"class":47},"University Hospital, Clermont-Ferrand",2,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":48},"100564858","phase-4-clozapine-related-immunodeficiency-in-parkinsons-disease-100564858","NCT06634641","Clozapine-related Immunodeficiency in Parkinsons Disease","Assessment of Clozapine-related Immunodeficiency Effect in Parkinsons Disease Patients","CLOZIDPD","Inclusion Criteria:\n\n* Patient ≥ 18 years old with Parkinson's disease according to MDS 2015 criteria\n* Psychotic symptoms requiring treatment with Clozapine\n* Patients with initially a normal leukocyte count (number of white blood cells\n\n  ≥ 3500\u002Fmm3 \\[3.5 x 109\u002Fl\\] and an absolute neutrophil count PNN ≥ 2000\u002Fmm3 \\[2 x 109\u002Fl\\])\n* patients in whom the number of white blood cells (WBC) and the absolute number of neutrophils (PNN) may be determined regularly at the following intervals: once a week during the first 18 weeks of treatment and, thereafter, at least every 4 weeks for the duration of the treatment. This monitoring must be continued throughout the treatment and for 4 weeks who follow the complete cessation of CLOZAPINE\n* Informed and written consent.\n* Affiliation to a social security system\n\nExclusion Criteria:\n\n* Patients with a contraindication to the use of Clozapine according to the summary of product characteristics (SPC)\n* Hypersensitivity to the active substance or to any of the excipients.\n* Patients who cannot receive regular blood tests.\n* History of granulopenia or toxic or idiosyncratic agranulocytosis (unless it results from previous chemotherapy).\n* History of agranulocytosis induced by CLOZAPINE\n* Treatment with CLOZAPINE should not be started at the same time as substances known to have a high potential for inducing agranulocytosis; The concomitant administration of depot antipsychotics is not recommended.\n* Functional bone marrow failure.\n* Uncontrolled epilepsy.\n* Alcoholic or induced psychosis, drug intoxication, comatose states.\n* Circulatory collapse and \u002F or CNS depression regardless of the aetiology.\n* Severe renal or cardiac disorders (eg: myocarditis).\n* Active liver disease with nausea, anorexia or jaundice; progressive liver disease, liver failure.\n* Paralytic ileus.\n* Patient with another potential cause of immunosuppression\n* Immunosuppressive or immune modulatory treatment active or stopped for less than 5 years\n* Anti-epileptic treatment active or stopped for less than 5 years\n* Chemotherapy active or stopped for less than 5 years\n* Solid or hematologic cancer active or treated for less than 5 years\n* Human immunodeficiency virus infection\n* Already known constitutional immune deficiency\n* Nephrotic syndrome\n* Protein-losing enteropathy\n* A history of radiotherapy\n* Long-term use of corticosteroids\n* Patient with potentially major cognitive disorders defined by a MoCA score less than or equal to 23\n* Pregnant or breastfeeding women\n* Patient under guardianship\u002Fcuratorship or deprived of liberty","18 Years",{"count":196,"type":22},24,[198],"PHASE4","Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia. In neurology, clozapine is frequently used and recommended to manage symptoms of psychosis associated with Parkinson's disease (PD). The risk of neutropenia or agranulocytosis associated with clozapine estimated at 1.3% is well known to doctors around the world with a peak at one month and a decrease in risk after more than a year of treatment. This risk has led to the policy of \"no blood, no drugs\" and monitoring of the complete blood count (CBC) weekly for 18 weeks and then monthly for the duration of treatment.\n\nSome studies suggest an increased risk of infections related to immunodeficiency induced by clozapine itself. This clozapine-induced immunodeficiency would be comparable to that encountered in patients with common variable immunodeficiency or under immunosuppressive treatment. In addition, this immunosuppressive effect linked to clozapine would not be dose dependent but time dependent. However, the only studies currently performed have been in psychiatric patients treated for schizophrenia.\n\nIt seems important to specifically explore clozapine-related immunodeficiency in PD patients treated with clozapine for PD-related psychosis. In this study, the investigators propose to evaluate the variations in serum immunoglobulin levels and lymphocyte subpopulations (B, T, NK) in parkinsonian patients treated with Clozapine at 6 months and 1 year after initiation of treatment.",[201,29,202,203],"Clozapine","Immunodeficiency","Psychosis",[205,206,207,208],"clozapine","parkinson's disease","immunodeficiency","psychosis","2025-11-17",{"date":211,"type":40},"2025-11-19",{"date":213,"type":40},"2024-10-01",{"date":152,"type":22},{"name":216,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":185},"100601037","closed-loop-therapeutic-refinement-using-local-field-potentials-in-parkinsons-disease-100601037","NCT07105280","Closed-Loop Therapeutic Refinement Using Local Field Potentials in Parkinson's Disease","CTRL-PD","Inclusion Criteria:\n\n* Patients with Parkinson's disease with bilateral DBS in the STN\n* DBS surgery with implantation of the Percept™ PC\u002FRC system performed at least 6 months ago\n* Symptoms such as dysarthria, freezing, or ON-OFF fluctuations that are insufficiently controlled\n* A usable LFP signal is present on at least one side\n\nExclusion Criteria:\n\n* Patients for whom switching to aDBS, operating the remote control independently, or making regular visits to the DBS center is deemed clinically unsafe or unreliable by the treating physician - for example, due to active or unstable cognitive or psychiatric conditions.\n* High impedance, defective DBS electrodes, or insufficient LFP signal quality, or bilateral stimulation primarily on the most ventral or dorsal contact points, preventing proper functioning of aDBS.\n* Patients who have objected to the use of their electronic health record data for medical scientific research.",{"count":86,"type":22},[25],"This multi-center pilot study compares conventional DBS (cDBS) and adaptive DBS (aDBS) in Parkinson's disease patients using the Medtronic Percept™ system.\n\nThe aim of the study is to identify which patients benefit most from aDBS, and to explore patient and LFP signal characteristics as well as stimulation parameters as potential predictors of treatment preference and efficacy. The study utilizes a blinded, randomized N-of-1 trial design, where each patient tests the following:\n\n* Original cDBS settings (cDBS);\n* Optimized cDBS settings (O-cDBS);\n* Optimized aDBS settings (O-aDBS) Each setting is evaluated for a minimum of 2 and maximum of 7 days at home in a randomized order (patient blinded).\n\nThe main study outcome consists of the patient's final preference among the three DBS programs: original cDBS, O-cDBS, or O-aDBS. Secondary outcomes focus on differences between cDBS, O-cDBS and O-aDBS regarding the following parameters (among others):\n\n* Quality of life (PDQ-39);\n* Patient satisfaction (5-point Likert Scale);\n* (Non)-motor fluctuations (MDS-UPDRS-III + MDS-NMS-Q);\n* Time spent in \"ON\"\u002F\"OFF\" motor phases (symptom diary + MDS-UPDRS IV);\n* Time spent experiencing dyskinesia (symptom diary + MDS-UPDRS IV);\n* Time spent with the most bothersome symptom (symptom diary + MDSUPDRS IV);\n* Stimulation parameters;\n* Local field potentials.\n\nThe study also incorporates real-world home-based assessments using the Experience Sampling Method (ESM) to capture motor and non-motor symptom fluctuations in daily life and identify differences among the three settings.",[29],[229,230,231,232,233,206],"deep brain stimulation","adaptive therapy","closed-loop therapy","local field potentials","subhtalamic nucleus","2025-09-30",{"date":236,"type":40},"2025-10-03",{"date":238,"type":22},"2025-10-01",{"date":240,"type":22},"2027-06-01",{"name":242,"class":47},"HagaZiekenhuis",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":16,"sex":17,"minAge":194,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":48},"100591025","novel-shoe-device-nushu-to-measure-gait-analysis-in-parkinsons-patients-100591025","NCT06975059","Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients","Using the NUSHU Shoe to Analyze Gait Balance and Vibrotactile Feedback in Early, Moderate and Advanced PD Patients and Healthy Controls","Parkinson's Disease:\n\nInclusion Criteria:\n\n1. Male or female ≥ 18 years of age.\n2. A diagnosis of Parkinson's disease\n3. Able to give written informed consent (as determined by the investigator)\n4. Can converse in English and read and perform all study activities\n5. Has willingness and ability to comply with study requirements\n\nExclusion Criteria:\n\n1. Diagnosis of an atypical parkinsonism syndrome, drug-induced parkinsonism, essential tremor, or other diagnoses that explain movement symptoms other than PD\n2. A diagnosis of significant CNS disease other than PD such as stroke, multiple sclerosis, epilepsy\n3. Persons with disorders other than PD significantly affecting gait as determined by the investigator\n4. History of MRI brain scan indicative of clinically significant abnormality as determined by the investigator\n5. Inability to wear interventional device\n6. Unable to ambulate independently at least with assistive walking device but without additional person assistance\n7. Pregnant or planning pregnancy within study timeframe\n8. Montreal Cognitive Assessment (MoCA) score \\\u003C 22 at screening\n9. Resides in a nursing home or assisted care facility\n\nHealthy Controls:\n\nInclusion Criteria:\n\n1. Male or female ≥ 18 years of age.\n2. No neurological disease or other significant gait impairment as deemed by the study investigator",{"count":251,"type":22},40,[25],"Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU by Magnes AG. The shoe additionally provides vibrational feedback that can potentially help gait difficulties experienced by Parkinson's patients.",[29],"2025-09-25",{"date":238,"type":40},{"date":258,"type":40},"2025-05-30",{"date":260,"type":22},"2030-07",{"name":262,"class":47},"Weill Medical College of Cornell University",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":109,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":48},"100603863","phase-1-safety-tolerability-and-exploratory-efficacy-of-ec5026-in-parkinsons-disease-step-study-100603863","NCT07142044","Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)","STEP","Inclusion Criteria:\n\n1. Adult males and females, 50 to 80 years of age (inclusive) at the time of Screening.\n2. Able to understand the consent form, and to provide voluntary written informed consent.\n3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.\n4. Confirmed diagnosis of idiopathic Parkinson's Disease according to 2015 Movement Disorder Society (MDS) clinical diagnostic criteria.\n5. Off state Hoehn \\& Yahr below Stage 3 at the time of Screening.\n6. Participants must be on stable doses of L-dopa with or without other adjunctive PD therapy for at least 30 days prior to enrollment. Doses should be expected to remain stable for the duration of the study.\n7. Participants must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements.\n8. Participants must have normal or not clinically significant clinical laboratory test results, as determined by the study investigator, including coagulation panel, blood cell counts, comprehensive metabolic panel analytes, and creatinine clearance (60 cm3\u002Fmin or greater). Clinical laboratory tests results that are consistent with known, stable comorbidities will be allowed as long as the comorbidities do not represent an exclusion criteria per se.\n9. Participants must have a negative urinary drug screen (UDS) for illicit drugs and a negative alcohol breath test.\n10. Abstention from use of other investigative or non-approved drugs for the duration of the trial\n11. Male participants who are not surgically sterile (vasectomized) and their female sexual partners must agree to use contraception during the study period and for 2 months after receiving the last dose of study drug.\n12. Male participants must not donate sperm during the study and for 12 months after receiving the last dose of study drug.\n13. Female participants must be non-pregnant, non-lactating, and either postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, 'clipping or tying tubes,' or hysterectomy) for at least 3 months, or they must agree to use two forms of highly effective contraception method (less than 1 pregnancy per 100 people using the method for one year) from 28 days and\u002For their last confirmed menstrual period prior to study enrollment (whichever is longer) until 2 months after receiving the last dose of study drug. Postmenopausal status will be defined as follows: minimum 1 year; amenorrhea duration of 12 consecutive months and a serum FSH value \\>40 IU\u002FL; postmenopausal status must be confirmed by an FSH test at Screening). Highly effective contraception methods include: Intra-uterine device (IUD) containing either copper or levonorgestrel (e.g., Mirena®), and\u002For barrier methods of contraception, including condoms (external or internal) and diaphragm ('cap'). Hormonal methods of contraception (with the exception of hormonal IUD) are not permitted within this study. Female participants will refrain from using hormonal contraceptives for at least 28 days prior to study entry until the end of the study period. Participants\u002FParticipant's partner(s) must also use a barrier form of contraception, from the first dose of study drug through until 2 months after the last dose. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Pre-Study Baseline (Day -1).\n14. Participants must be able to speak, read, and understand English sufficiently to allow comprehension and completion of all study assessments.\n\nExclusion Criteria:\n\n1. Atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs or toxins, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or non-PD degenerative disease).\n2. Family history of early onset PD (age \\\u003C50 years) or known personal genetically causal etiology of PD.\n3. Diagnosis of any other clinically significant neurologic disease that may confound the assessment of the study drug on PD symptoms\n4. Not stabilized with current therapeutic regimen for PD or likely to require changes in L-dopa therapy over the duration of the trial.\n5. Presence of PD psychosis or dementia, or other neuropsychiatric or psychiatric conditions impeding informed consent or compliance with study interventions.\n6. Severe dyskinesia (defined as per MDS-UPDRS) during a \"normal day\" that would significantly interfere with the participant's ability to perform study assessments.\n7. History of neurosurgery for PD or tremor.\n8. Clinically significant medical, surgical, or laboratory abnormalities in the judgement of the Investigator.\n9. Participants with any clinically unstable or significant cardiovascular (including acute coronary syndrome within the prior year to Screening), renal, hepatic, respiratory, gastrointestinal, hematological, endocrine, or infectious disease (including HIV infection).\n10. Participants with clinically significant abnormalities on screening vital signs, laboratory tests, and\u002For ECG, per investigator's judgement. Participants with poor venous access will also be excluded.\n11. Participants with a family history of significant cardiac disease (i.e., sudden death in first degree relative; myocardial infarction before the age of 50).\n12. Participants with a history of disorders of the hypothalamic-pituitary-adrenal axis, including adrenal insufficiency and Cushing's, or with a history of disorders of the hypothalamic-pituitary-gonadal axis, including hypogonadism.\n13. Participants with any of the following blood values at screening:\n\n    * Abnormal plasma renin and\u002For aldosterone value\n    * Morning cortisol level \\\u003C5 mcg\u002FdL\n    * ACTH stimulated cortisol levels \\\u003C18 mcg\u002FdL at 60 minutes after ACTH injection at screening, or\n    * Abnormal FSH, LH, testosterone (for males), or estradiol (for females, unless post-menopausal)\n14. Participants who have used any topical, oral, or intravenous exogenous corticosteroids within 12 weeks and\u002For intra-articular exogenous corticosteroids within 6 months prior to the start of the trial, or who plan on using them during the study.\n15. Participants who have used chemotherapy agents, or who have a personal history of cancer or cancer in first degree relatives suggestive of elevated cancer risk, other than nonmetastatic skin cancer that has been completely excised, within 5 years prior to Screening.\n16. Participants who have used (within 14 days of randomization) or plan on using during the duration of the study any prescription or over-the-counter drugs that are moderate or strong CYP3A4 inducers or inhibitors.\n17. Participants who have used (within 14 days of randomization) or plan on using during the duration of the study any dietary aids, supplements, or foods that are moderate or strong CYP3A4 inhibitors (e.g., grapefruit juice).\n18. Participants with difficulty in swallowing oral medications\n19. Participants who have used any other investigational drug within 1 month or 5 half-lives, whichever is longer, prior to enrollment.\n20. Participants with a documented history of difficult lumbar puncture procedures, to the investigator's discretion.",{"count":271,"type":22},18,[273,274],"PHASE1","PHASE2","The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are:\n\n* Is EC5026 safe in adults with Parkinson's Disease?\n* What are the levels of EC5026 achieved after oral administration for 28 days?\n* What molecules or pathways does EC5026 target, and to what extent?\n\nIn addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease.\n\nResearchers will compare EC5026 to a placebo (a look-alike substance that contains no drug).\n\nParticipants will:\n\n* Take EC5026 or a placebo every day for 28 consecutive days\n* Visit the clinic for frequent checkups, blood tests, spinal fluid tests, and questionnaires",[29],[278,279,280,281,282],"EC5026","Parkinson's Disease","Soluble Epoxide Hydrolase","sEH","Soluble Epoxide Hydrolase inhibitor","2025-08-29",{"date":285,"type":40},"2025-09-05",{"date":287,"type":22},"2025-10",{"date":289,"type":22},"2027-06",{"name":291,"class":292},"EicOsis Human Health Inc.","INDUSTRY",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":301,"maxAge":109,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100600408","parkinsons-research-in-metagenomic-early-stage-biomarkers-100600408","NCT07097103","Parkinson's Research In Metagenomic Early Stage Biomarkers","A 2x2 Factorial Randomized Controlled Non-pharmacological Interventional Multicenter Pilot Study on the Influence of the Mediterranean Diet and Physical Exercise on the Microbiome of Patients With Parkinson's Disease","PRIME_2025","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease according to United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria;\n* aged 35-80 years;\n* Hoehn \\& Yahr stage \\> 1 and \\\u003C 3 in the clinical \"ON\" state;\n* MoCA score ≥17.54;\n* MMSE ≥24;\n* Stable dopaminergic midication regimen for ≥ 4 weeks;\n* Ability to interact with the research team and provide informed consent in Italian;\n* Suitable to physical exercise;\n* Able to walk unassisted (no walking aids);\n* Willingness and ability to comply with all study procedures;\n* Willingness to maintain usual diet during a ≥ 4-week pre-baseline period;\n* Willingness to switch to a Mediterranean-style diet during the intervention;\n* Ability to provide stool samples at each collection timepoint;\n* Willing to avoid strenuous exercise and alcohol for 24 hours prior to each visits.\n\nExclusion Criteria:\n\n* Pre-existing psychiatric disorders;\n* Atypical or secondary Parkinsonism;\n* Presence of pacemakers or other subcutaneous electronic devices;\n* Any other neurological or neurodegenerative disorders;\n* Moderate to severe cognitive decline;\n* Beck Depression Inventory-II (BDI-II)\\] score ≥28;\n* Dementia diagnosis;\n* Thyroid dysfunctions;\n* Type1 Diabetes Mellitus;\n* Type 2 diabetes mellitus with HbA₁c ≥ 8% or on insulin therapy;\n* Acute diseases;\n* Active Neoplasia;\n* IBD or IBS;\n* Celiac disease;\n* History of major gastrointestinal surgery or acute GI conditions (e.g., gastroenteritis) within the past 3-6 months;\n* Chronic corticosteroid therapy;\n* Use of proton pump inhibitors within the past 30 days;\n* Acute, antibiotic-resistant infections;\n* Antibiotic intake within the past 30 days;\n* Prebiotic\u002Fprobiotic supplement use in the past 30 days;\n* Prolonged intake of anxiolytic drugs, antidepressants, antipsychotics, cognitive stimulants, and analogs in the past 3 months;\n* Underweight (BMI \\\u003C18.5);\n* History of deep brain stimulation (DBS) surgery;\n* Pregnancy or lactation;\n* Regular use of enemas or suppositories to alleviate constipation;\n* Use of experimental products in the 3 months prior to the screening visit\n* Patients who, for medical reasons, are required to follow special dietary regimens that could interfere with the adoption or effectiveness of the Mediterranean model;\n* Vegan\u002FVegetarian diet or any other dietary behaviour that excludes one or more of the typical food groups of the Mediterranean model.","35 Years",{"count":303,"type":22},80,[25],"This 2x2 factorial, randomized, controlled pilot study aims to identify a specific microbiota pattern, which could constitute a biomarker of Parkinson's disease, and to evaluate whether specific pathotypes can be associated with different stages of the disease; furthermore, the investigators are committed to evaluating how and to what extent the changes induced by a personalized nutritional intervention combined with physical exercise affect the symptoms and quality of life of patients.",[29],[308,309,310,311,312],"Physical activity","Mediterranean Diet","Pilot study","Microbiome","Parkinson's disease","2025-07-30",{"date":315,"type":40},"2025-07-31",{"date":317,"type":22},"2025-09-01",{"date":319,"type":22},"2029-07-31",{"name":321,"class":47},"IRCCS San Raffaele Roma",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":16,"sex":17,"minAge":329,"maxAge":109,"enrollmentInfo":330,"targetDuration":4,"studyType":332,"phases":4,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":48},"100587768","perception-of-affordances-and-obstacle-crossing-in-people-with-parkinsons-disease-and-healthy-adults-100587768","NCT06932679","Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults","Affordances and Impairments: A Paradigm for Understanding Obstacle Crossing in Parkinson's Disease","Inclusion Criteria:\n\n* Participants aged 20 to 80 years.\n* Ability to walk independently outdoors without assistive devices.\n* For Parkinson's Disease (PD) group: Diagnosis of PD confirmed by medical records.\n* For healthy control groups: No neurological or orthopedic conditions affecting gait.\n\nExclusion Criteria:\n\n* Feezing of gait (for PD group only), based on a score greater than 0 on the Freezing of Gait Questionnaire.\n* Severe visual impairment that cannot be corrected with glasses or lenses.\n* Cognitive impairment, defined as a score below 18 on the telephone-based Mini-Mental State Examination (MMSE).\n* Any orthopedic condition, pain, or other medical condition that may affect walking, based on self-report.","20 Years",{"count":331,"type":22},180,"OBSERVATIONAL","This study aims to explore how young adults, older adults and people with Parkinson's disease (PwP), perceive their abilty to cross obstacles while walking, and how this perception is related to their actual performance of obstacle crossing and disease-related motor and cognitive impairments. The study will explore this percepeption and the actual performance in different walking environments(floor, synthetic grass turf). Understanding how people perceive obstacles may help improve rehabilitation methods and reduce the risk of falls. The study will take place at the Motor Performance Laboratory, University of Haifa, and will include walking tasks, eye-tracking measurements, and motor and cognitive assessments.",[29],[279,336,337,338,339,340,341,342,343],"Obstacle Crossing","Gait","Affordances","Motor Control","Balance","Fall Risk","Visual Exploration","Gaze Behavior","2025-07-17",{"date":346,"type":40},"2025-07-22",{"date":348,"type":40},"2025-04-24",{"date":350,"type":22},"2028-06-24",{"name":352,"class":47},"University of Haifa",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":17,"minAge":361,"maxAge":4,"enrollmentInfo":362,"targetDuration":363,"studyType":332,"phases":4,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":48},"100593982","characterising-physiological-resilience-in-people-with-parkinsons-disease-100593982","NCT07013513","Characterising Physiological Resilience in People With Parkinson's Disease","Characterising the Physiological Resilience of People With Parkinson's Disease - With Feasibility","ParkEx","Inclusion Criteria:\n\n* Participants who are willing and able to give informed consent for participation in the study\n* Participants who can walk 30 meters with or without walking aids\n* Participants who have a confirmed diagnosis of Parkinson's disease by a healthcare professional.\n\nExclusion Criteria:\n\n* Cardio- and\u002For pulmonary diseases except for well-controlled hypertension and asthma\n* Severe cognitive impairment\u002Fdementia\n* Joint disorders preventing exercise participation\n* Current or recent (\\\u003C2 years) malignancy (excluding minor cancers such as skin cancer, or not receiving chemotherapy or radiotherapy within the last 3 months)","40 Years",{"count":5,"type":22},"1 Day","Parkinson's disease (PD) is a condition that affects movement and gets worse over time. It is more common in older adults. People with PD may have symptoms like shaking, stiff muscles, slow movement, and trouble with balance. They may also experience other issues like pain, depression, anxiety, and memory problems, which can make daily life harder.\n\nPhysiological resilience is the body's ability to recover or stay strong despite challenges like aging or illness. People with low resilience may struggle to cope with illness, become less active, and have a higher risk of weakness or hospitalization. Since both PD and low resilience are more common in older adults, understanding how PD affects resilience can help improve care.\n\nThis study will look at resilience in people with PD by measuring heart, lung, muscle, coordination, memory, and thinking abilities. It will also compare two types of single-session aerobic exercise-cycling and walking on a treadmill-regarding participants' perspectives. Participants will be randomly chosen to do one of these exercises for 40 minutes at a moderate level. Afterward, they will share their thoughts on how enjoyable and comfortable the exercise was and whether they would continue doing it.\n\nAerobic exercise is often recommended for people with PD, but it is unclear which type is best for people with PD and which type is mostly preferred by participants with PD. The results of this study will help practitioners make better exercise recommendations for people with PD, leading to better symptom management and a higher quality of life.",[29],[367],"Parkinson's Disease, elderly, resilience, characterisation, aerobic exercise, feasibility","2025-06-01",{"date":370,"type":40},"2025-06-10",{"date":368,"type":22},{"date":373,"type":22},"2026-10-01",{"name":375,"class":47},"University of Nottingham",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":194,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":4},"100591939","the-effects-of-ballet-based-exercise-training-on-respiratory-functions-balance-cognitive-functions-peripheral-muscle-strength-functional-capacity-and-quality-of-life-in-patients-with-parkinsons-disease-100591939","NCT06986941","The Effects of Ballet-Based Exercise Training on Respiratory Functions, Balance, Cognitive Functions, Peripheral Muscle Strength, Functional Capacity and Quality of Life in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with Parkinson's disease.\n* Modified Hoehn and Yahr stages I to III.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Joint deformities or severe movement limitations that prevent participation in dance exercises.\n* Mental retardation (severe cognitive impairment).\n* Major surgery within the past 6 months.\n* Presence of uncontrolled cardiovascular, pulmonary, or oncological diseases.\n* Diagnosed visual or auditory impairments affecting balance.",{"count":196,"type":22},[25],"This study investigates the impact of an 8-week ballet-based dance therapy on people with Parkinson's disease. It aims to assess the effect of ballet on motor and non-motor symptoms, such as balance, cognitive function, functional capacity, and quality of life. The study will provide insights into the potential of ballet therapy as an effective, non-pharmacological treatment for Parkinson's disease.",[29],[387,388,340,389,390],"Ballet-based Dance Therapy","Respiratory Function","Cognitive Function","Quality of Life","2025-05-22",{"date":393,"type":40},"2025-05-23",{"date":395,"type":22},"2025-06",{"date":397,"type":22},"2027-02",{"name":399,"class":47},"Bezmialem Vakif University",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":332,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100582043","research-on-the-brain-glymphatic-system-of-parkinsons-disease-patients-based-on-dti-technology-100582043","NCT06858176","Research on the Brain Glymphatic System of Parkinson's Disease Patients Based on DTI Technology","Inclusion Criteria:(1) All the selected candidates were diagnosed in accordance with the \"Diagnostic Criteria for Parkinson's Disease in China\" (2016 edition) formulated by the International Society of Parkinson's Disease and Movement Disorders and the Parkinson's Disease and Movement Disorders Group and Special Committee of China; (2) Able to cooperate with and tolerate cranial magnetic resonance examination; (3) All are effective against dopamine drugs.\n\n\\- Exclusion Criteria:(1) secondary parkinsonism (such as after encephalitis, long-term use of neuroleptics such as phenothiazines and butyryls and other drugs such as reserpine, history of toxic exposure, history of vascular diseases such as cerebral infarction or hemorrhage in the basal ganglia, history of traumatic brain injury, abnormal thyroid function, etc.); (2) Parkinson's superposition syndrome (such as progressive supranuclear palsy, olivine pontine cerebellar atrophy, corticobasal ganglia degeneration, Lewy body dementia, Shv. Dräger syndrome, etc.); (3) hereditary degenerative parkinsonism; (4) Patients with diabetes mellitus and end-stage renal disease; (5) Those with contraindications to magnetic resonance examination.\n\n\\-","82 Years",{"count":408,"type":22},150,"Synopsis：The brain glymphatic system is a newly discovered anatomical system for removing waste products and maintaining homeostasis in the brain, and its damage is closely related to a variety of neurological diseases. The diffusion tensor image-analysis along the perivascular space (DTI-ALPS) technique has the advantage of being non-invasive and has been shown to be useful for assessing brain glymphatic system function. The purpose of this study is to use DTI-ALPS technology to evaluate the functional changes of the brain glymphatic system in patients with primary Parkinson's disease at different stages of the disease .\n\nImpact:DTI-ALPS technology is a potential imaging indicator for early diagnosis and monitoring of Parkinson's disease progression, and has definite value for clinical application.\n\nPurpose :the functional changes of brain glymphatic system in patients with Parkinson's disease at different stages of the disease will be investigated based on DTI-ALPS technology Methods:The clinical data of 100 patients with primary Parkinson's disease will be admitted to the First People's Hospital of Yunnan Province from March 2025 to April 2026 wil be prospectively collected, and they will be divided into two groups: 50 patients with early Parkinson's disease and 50 patients with late Parkinson's disease according to the Hoehn-Yahr Scale , and 50 healthy volunteers (HC) matched with them will be collected. All subjects will be scanned with a 3.0 T MRI system（MAGNETOM Prisma,Siemens Healthcare,Erlangen,Germany）.The scanning sequences included conventional MRI noncontrast and DTI sequences, which acquired images of b=0 s\u002Fmm² and b=1000 s\u002Fmm²4. FSL and ITK-SANP software will be used to delineate circular ROIs with voxel diameters of 5 mm in the projection fiber and contact fiber regions at the bilateral ventricular body level of the anisotropy score map, and the diffusivity of each fiber on the x, y, and z axes will be measured, and the DTI-ALPS index value will be calculated, and the one-way ANOVA wii be performed by IBM SPSS statistic 25.0 software, and the differences in the mean ALPS values of the left brain, right brain, and both sides of the subjects in the three groups will be compared. The correlation between the index and clinical data such as age, course of disease, Mini-Mental State Examination Score (MMSE), Montreal Cognitive Assessment Scale, Quality of Life Questionnaire for Patients with Parkinson's Disease (PDQ-39), Parkinson's Disease Non-motor Symptom Evaluation Scale (NMSS), Hamilton Depression Rating Scale score(HAMD), and Unified Parkinson's Rating Scale score (URPDS)will be analyzed.",[411,29,412],"Glymphatic System","DTI","2025-02-27",{"date":415,"type":40},"2025-03-05",{"date":417,"type":22},"2025-03",{"date":419,"type":22},"2026-04",{"name":421,"class":47},"The First People's Hospital of Yunnan",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":194,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":48},"100573143","constant-current-versus-constant-voltage-subthalamic-nucleus-deep-brain-stimulation-in-patients-with-parkinsons-disease-100573143","NCT06742450","Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease","Prospective Study of Constant Current Versus Constant Voltage Deep Brain Stimulation in Patients with Parkinson's Disease","Inclusion Criteria:\n\n* Patients with idiopathic Parkinson's disease\n* Aged 18 to 75, no limited sex\n* After bilateral STN-DBS, yet not powered on\n\nExclusion Criteria:\n\n* Mental disorders or dementia\n* Pregnant, lactating women or women who are unable to take effective measures to prevent pregnancy\n* Serious health conditions, such as tumors, liver or kidney diseases, etc.\n* Epilepsy or other seizure disorders\n* Patients with severely deviated electrode placement\n* Patients who were unable to voluntarily sign an informed consent form\n* Patients who did not agree to cooperate with follow-up","75 Years",{"count":331,"type":22},[25],"To compare the efficacy, programming burden, power consumption, and physicians' and patients' satisfaction between current mode and voltage mode of deep brain stimulation in each period one year after surgery.",[29],"2024-12-16",{"date":436,"type":40},"2024-12-19",{"date":438,"type":40},"2024-01-27",{"date":440,"type":22},"2026-08-31",{"name":442,"class":47},"Xuanwu Hospital, Beijing"]